Prescriptions of psychotropic and somatic medications among patients with severe mental disorders and healthy controls in a naturalistic study

References

• Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014;13(2):153–160. doi: 10.1002/wps.20128.
   PubMed Web of Science ®Google Scholar
• John A, McGregor J, Jones I, et al. Premature mortality among people with severe mental illness – new evidence from linked primary care data. Schizophr Res. 2018;199:154–162. doi: 10.1016/j.schres.2018.04.009.
   PubMed Web of Science ®Google Scholar
• Bowie CR, Depp C, McGrath JA, et al. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am J Psychiatry. 2010;167(9):1116–1124. doi: 10.1176/appi.ajp.2010.09101406.
   PubMed Web of Science ®Google Scholar
• Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64(1):19–28. doi: 10.1001/archpsyc.64.1.19.
   PubMed Web of Science ®Google Scholar
• Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–180. doi: 10.1002/wps.20420.
   PubMed Web of Science ®Google Scholar
• De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412–424. doi: 10.1016/j.eurpsy.2009.01.005.
   PubMed Web of Science ®Google Scholar
• Holt RI, Abdelrahman T, Hirsch M, et al. The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. J Psychopharmacol. 2010;24(6):867–873. doi: 10.1177/0269881109102788.
   PubMed Web of Science ®Google Scholar
• Crump C, Winkleby MA, Sundquist K, et al. Comorbidities and mortality in persons with schizophrenia: a Swedish National Cohort Study. Am J Psychiatry. 2013;170(3):324–333. doi: 10.1176/appi.ajp.2012.12050599.
   PubMed Web of Science ®Google Scholar
• Dalkner N, Bengesser SA, Birner A, et al. Metabolic syndrome impairs executive function in bipolar disorder. Front Neurosci. 2021;15:717824. doi: 10.3389/fnins.2021.717824.
   PubMed Web of Science ®Google Scholar
• Filipčić I, Šimunović Filipčić I, Grošić V, et al. Patterns of chronic physical multimorbidity in psychiatric and general population. J Psychosom Res. 2018;114:72–80. doi: 10.1016/j.jpsychores.2018.09.011.
   PubMed Web of Science ®Google Scholar
• Steinhausen HC. Recent international trends in psychotropic medication prescriptions for children and adolescents. Eur Child Adolesc Psychiatry. 2015;24(6):635–640. doi: 10.1007/s00787-014-0631-y.
   PubMed Web of Science ®Google Scholar
• Abdullah-Koolmees H, Gardarsdottir H, Stoker LJ, et al. Prevalence of medication use for somatic disease in institutionalized psychiatric patients. Pharmacopsychiatry. 2013;46(7):274–280. doi: 10.1055/s-0033-1354405.
   PubMed Web of Science ®Google Scholar
• Heiberg IH, Jacobsen BK, Balteskard L, et al. Undiagnosed cardiovascular disease prior to cardiovascular death in individuals with severe mental illness. Acta Psychiatr Scand. 2019;139(6):558–571. doi: 10.1111/acps.13017.
   PubMed Web of Science ®Google Scholar
• Puntervold OE, Kruckow L, Banner J. Undiagnosed disease in decedents with and without schizophrenia: an autopsy-based case-control study. Nord J Psychiatry. 2021;75(8):568–573. doi: 10.1080/08039488.2021.1905877.
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Goracci A. The effects of undertreated chronic medical illnesses in patients with severe mental disorders. J Clin Psychiatry. 2009;70(Suppl. 3):22–29. doi: 10.4088/JCP.7075su1c.04.
   PubMed Web of Science ®Google Scholar
• Shtasel DL, Gur RE, Mozley PD, et al. Volunteers for biomedical research. Recruitment and screening of normal controls. Arch Gen Psychiatry. 1991;48(11):1022–1025. doi: 10.1001/archpsyc.1991.01810350062010.
   PubMed Web of Science ®Google Scholar
• Pavletic AJ. Why knowing healthy controls matters. Int J Clin Pract. 2020;74(1):e13424. doi: 10.1111/ijcp.13424.
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV axis I disorders, clinician version (SCID-CV). Washington (DC): American Psychiatric Press, Inc.; 1996.
   Google Scholar
• Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA. 1994;272(22):1749–1756. doi: 10.1001/jama.272.22.1749.
   PubMed Web of Science ®Google Scholar
• Nesvåg R, Jönsson EG, Bakken IJ, et al. The quality of severe mental disorder diagnoses in a National Health Registry as compared to research diagnoses based on structured interview. BMC Psychiatry. 2017;17(1):93. doi: 10.1186/s12888-017-1256-8.
   PubMedGoogle Scholar
• WHO Collaborating Centre for Drug Statistics Methodology: guidelines for ATC classification and DDD assignment; 2020. Available from: https://www.whocc.no/atc/structure_and_principles
   Google Scholar
• McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19–32. doi: 10.1016/j.schres.2005.07.014.
   PubMed Web of Science ®Google Scholar
• Ribe AR, Laursen TM, Sandbaek A, et al. Long-term mortality of persons with severe mental illness and diabetes: a population-based cohort study in Denmark. Psychol Med. 2014;44(14):3097–3107. doi: 10.1017/S0033291714000634.
   PubMed Web of Science ®Google Scholar
• Brink M, Green A, Bojesen AB, et al. Excess medical comorbidity and mortality across the lifespan in schizophrenia: a nationwide Danish Register Study. Schizophr Res. 2019;206:347–354. doi: 10.1016/j.schres.2018.10.020.
   PubMed Web of Science ®Google Scholar
• Nielsen RE, Kugathasan P, Straszek S, et al. Why are somatic diseases in bipolar disorder insufficiently treated? Int J Bipolar Disord. 2019;7(1):12. doi: 10.1186/s40345-019-0147-y.
   PubMedGoogle Scholar
• Horsdal HT, Benros ME, Köhler-Forsberg O, et al. Metabolic profile at first-time schizophrenia diagnosis: a population-based cross-sectional study. Neuropsychiatr Dis Treat. 2017;13:621–630. doi: 10.2147/NDT.S119632.
   PubMed Web of Science ®Google Scholar
• Rajkumar AP, Horsdal HT, Wimberley T, et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. Am J Psychiatry. 2017;174(7):686–694. doi: 10.1176/appi.ajp.2016.16040442.
   PubMed Web of Science ®Google Scholar
• Vedal TSJ, Steen NE, Birkeland KI, et al. Free thyroxine and thyroid-stimulating hormone in severe mental disorders: a naturalistic study with focus on antipsychotic medication. J Psychiatr Res. 2018;106:74–81. doi: 10.1016/j.jpsychires.2018.09.014.
   PubMed Web of Science ®Google Scholar
• Stubbs B, Thompson T, Acaster S, et al. Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies. Pain. 2015;156(11):2121–2131. doi: 10.1097/j.pain.0000000000000304.
   PubMed Web of Science ®Google Scholar
• Stubbs B, Mitchell AJ, De Hert M, et al. The prevalence and moderators of clinical pain in people with schizophrenia: a systematic review and large scale meta-analysis. Schizophr Res. 2014;160(1–3):1–8. doi: 10.1016/j.schres.2014.10.017.
   PubMed Web of Science ®Google Scholar
• Stubbs B, Eggermont L, Mitchell AJ, et al. The prevalence of pain in bipolar disorder: a systematic review and large-scale meta-analysis. Acta Psychiatr Scand. 2015;131(2):75–88. doi: 10.1111/acps.12325.
   PubMed Web of Science ®Google Scholar
• Köhler O, Petersen L, Mors O, et al. Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes. Brain Behav. 2015;5(8):e00338. doi: 10.1002/brb3.338.
   PubMed Web of Science ®Google Scholar
• Baumeister H, Balke K, Härter M. Psychiatric and somatic comorbidities are negatively associated with quality of life in physically ill patients. J Clin Epidemiol. 2005;58(11):1090–1100. doi: 10.1016/j.jclinepi.2005.03.011.
   PubMed Web of Science ®Google Scholar
• Pavletic A, Pao M. Safety, science, or both? Deceptive healthy volunteers: psychiatric conditions uncovered by objective methods of screening. Psychosomatics. 2017;58(6):657–663. doi: 10.1016/j.psym.2017.05.001.
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Davis JM, Hedeker DR. A comment on the selection of ‘healthy controls’ for psychiatric experiments. Arch Gen Psychiatry. 1990;47(8):785–786. doi: 10.1001/archpsyc.1990.01810200093014.
   PubMed Web of Science ®Google Scholar
• Jönsson EG, Saetre P, Vares M, et al. Use of antipsychotics – an analysis of lifetime treatment in 66 patients with psychoses. Psychiatry Res. 2011;187(1–2):80–88. doi: 10.1016/j.psychres.2010.10.027.
   PubMed Web of Science ®Google Scholar
• Vares M, Saetre P, Strålin P, et al. Concomitant medication of psychoses in a lifetime perspective. Hum Psychopharmacol. 2011;26(4–5):322–331. doi: 10.1002/hup.1209.
   PubMed Web of Science ®Google Scholar
• Statistics Norway: Statistikkbanken. Statistics Norway; 2023. Available from: https://www.ssb.no/statbank/table/06922
   Google Scholar